MedPath

Gastric Neuromuscular Function in GERD

Not Applicable
Recruiting
Conditions
GERD
Interventions
Device: Body Surface Gastric Mapping
Registration Number
NCT05719168
Lead Sponsor
The Functional Gut Clinic
Brief Summary

Bodysurface gastric mapping (BSGM) will be used to assess gastric neuromuscular function in healthy controls and patients with medical refractory gastroesophageal reflux disease (GERD).

Participants will undergo BSGM for 4-hours in addition to high resolution manometry (HRM), pH-impedance monitoring, and gastric emptying breath test.

Detailed Description

This is a clinical trial of a non-invasive BSGM medical device (Gastric Alimetry) in patients with medical refractory GORD and healthy controls to determine the differences in gastric electrical activity, and correlate with adjacent measurements of gastro-esophageal function.

Patients referred to the Functional Gut Clinic for standard care investigation of GORD with HRM and pH-impedance monitoring will be recruited. Healthy volunteers will be recruited via advertisement.

All patients and healthy volunteers will undergo BSGM at the research site, which lasts around 4.5 hours. After a 0.5 hour baseline, subjects will undergo HRM and pH-impedance monitoring concomitantly. A test meal of porridge with C13 labelled octanoic acid will be consumed with BSGM and breath samples recorded for 4.0 hours after meal completion. The HRM catheter will be removed after 1.0 hour from finishing the test meal whist the pH-impedance monitoring will continue for the remainder of the site visit and for the remainder of the 24-hour study period whilst the subject is at home to quantify reflux.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Aged 18-70 years old
  • BMI 18-35
  • Able to understand written and spoken English
  • Able to provide written consent
  • Able to understand risks and benefits
Exclusion Criteria
  • Antacid use (e.g. PPI, H2RA or Gaviscon) within last 12-months
  • Active use of other medications known to impact gastric motility
  • Upper GI symptoms including but not limited to heartburn, regurgitation, epigastric pain, nausea and bloating
  • Significant medical condition
  • History of skin allergies or hypersensitivity
  • Active abdominal wounds or abrasions, fragile skin
  • Current pregnancy
  • Vulnerable group e.g. prisoners/cognitive impairment/institutionalised individuals
  • Regular cannabis users (unable to abstain for 7-days)
  • Opioid user
  • Unable to use a tablet device

GORD patients

Inclusion Criteria

  • Referred for 24-hour pH-impedance monitoring
  • Aged 18-70 years old
  • BMI 18-35
  • Able to understand written and spoken English
  • Able to provide written consent
  • Able to understand risks and benefits

Exclusion Criteria

  • Systemic or metabolic disorder known to cause gastric dysmotility other than diabetes (e.g. scleroderma, multiple sclerosis, hyperthyroidism).
  • History of upper GI surgery or hiatal hernia (>5cm, paraesophageal, or 'large' on endoscopy report)
  • Diabetic and on insulin
  • Proven mechanical bowel obstruction
  • History of skin allergies or hypersensitivity
  • Active abdominal wounds or abrasions, fragile skin
  • Current pregnancy
  • Vulnerable group - prisoners/cognitive impairment/institutionalised individuals
  • Regular cannabis users (unable to abstain for 7-days)
  • Opioid user
  • Unable to use a tablet device

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Patients with medical refractory GERDBody Surface Gastric MappingParticipants undergo BSGM for 4.5 hours with simultaneous oesophageal manometry, pH-impedance monitoring and gastric emptying breath tests. Following completion, participants continue with ambulatory pH-impedance monitoring for a further 24-hours. Participants undergo a hydrogen and emthane breath test on a seperate day.
Healthy controls without gastrointestinal symptomsBody Surface Gastric MappingParticipants undergo BSGM for 4.5 hours with simultaneous oesophageal manometry, pH-impedance monitoring and gastric emptying breath tests. Following completion, participants continue with ambulatory pH-impedance monitoring for a further 24-hours.
Primary Outcome Measures
NameTimeMethod
Difference in BSGM parameters between GORD and healthy controls24-hours

% of retrograde activity

Secondary Outcome Measures
NameTimeMethod
Correlate reflux event frequency with Fed:Fasted Amplitude ratio24-hours

Frequency of reflux events with Fed:Fasted Amplitude ratio

Correlate reflux event frequency with Prinicpal Gastric Frequency (cpm)24-hours

Frequency of reflux events with Prinicpal Gastric Frequency (cpm)

Correlate reflux event frequency with % of retrograde activity24-hours

Frequency of reflux events with % of retrograde activity

Correlate symptom severity with BSGM parameters24-hours

Real time discrete (vomiting, belching, reflux counts) and continuous (Nausea, bloating, upper gut pain, heartburn, stomach burn and excessive fullness) gastrointestinal symptom scores at both pre- and post-prandial time periods determined by a series of multiple 10-point symptom severity scales integrated within the validated Gastric Alimetry iOS Application with Gastric Alimetry Rhythm Index

Correlate the results of gastric emptying with BSGM parameters24-hours

T lag and T 1/2 (minutes) with ith Gastric Alimetry Rhythm Index

Correlate reflux event frequency with Average Amplitude24-hours

Frequency of reflux events with Average Amplitude (microvolts)

Correlate the results of oesophageal manometry with Prinicpal Gastric Frequency24-hours

Integrated relaxation pressure (mmHg) with % of retrograde activity

Correlate quality of life with BSGM parameters24-hours

Total symptom burden scores according to the PAGI-QOL with Gastric Alimetry Rhythm Index

Correlate the results of oesophageal manometry with BSGM parameters24-hours

Distal contractile integral (mmHg.s.cm) with Gastric Alimetry Rhythm Index

Correlate the results of oesophageal manometry with Gastric Alimetry Rhythm Index24-hours

Frequency of transient lower oesophageal sphincter relaxation (TLOSRs) with Prinicpal Gastric Frequency

Correlate the results of hydrogen and methane breath testing with Gastric Alimetry Rhythm Index7 days

Total gas production (AUC ppm) with Gastric Alimetry Rhythm Index

Correlate the results of oesophageal manometry with % of retrograde activity24-hours

Frequency of transient lower oesophageal sphincter relaxation (TLOSRs) with % of retrograde activity

Correlate reflux event frequency with Gastric Alimetry Rhythm Index24-hours

Frequency of reflux events with Gastric Alimetry Rhythm Index

Normal reference ranges for gastric emptying and BSGM24-hours

T lag and T 1/2 time (minutes)

Trial Locations

Locations (1)

The Functional Gut Clinic

🇬🇧

Manchester, Greater Manchester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath